1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)

Authors :: Z. Wu
M. Xiao
Kang Li
Y. Cao
Y. Chen
H. Duan
Z. Ma
Xingxiang Pu
Q. Wang
J. Weng
Jianjun Li
Zefen Xiao
Peiguo Cao
Yujin Xu
Huilai Zhang
Lingqian Wu
Source :: Annals of Oncology. 32:S970
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Second line treatment
Docetaxel
business.industry
Internal medicine
Phase (matter)
medicine
Hematology
business
medicine.drug

Full Text Access

Tools